pegasys hcv

24 weeks of total treatment, with RG7128 500 mg BID [twice daily] in combination with Pegasys and ribavirin for 12 weeks, followed by 12 weeks of Pegasys and ribavirin ("12+12") 24 weeks of total treatment, with RG7128 1000 mg BID in combination with Pegasys and ribavirin for 12 weeks, followed by 12 weeks of Pegasys and ribavirin ("12+12") 24 weeks of total treatment, with RG7128 1000 mg BID in combination with Pegasys and ribavirin for 8 weeks, followed by a further 16

About the RG7128 Phase 2b Trial The Phase 2b trial is anticipated to enroll a total of about 400 HCV-infected patients with genotypes 1 or 4 who have never received HCV treatment.

s transplant center is proposing 1 year of Pegasys (180mcg) and Ribavirin (1000mg) followed by a year of Pegasys alone to treat his recurrent HCV. Have you heard of that kind of treatment before? Why would the 2nd year be Pegasys alone? What do you do at your center in this situation? Do you feel that it is important to get a viral load test at 4 weeks? How often should the viral load test be done? What is the procedure at your center? Thank you for your advice.

The Foundation and Future of HCV Treatment Combination therapy of pegylated interferon and ribavirin is the current standard of care for HCV. PEGASYS is the leading treatment for HCV, and also is the pegylated interferon therapy of choice for most HCV antiviral agents in development -- including those developed through collaborations with Roche, as well as those developed by other companies.

I was wondering if there have been any studies comparing Pegasys and Pegintron, and if one has better SVR numbers than the other or was more tolerable. I am new here so I hope I am posting this in the correct forum.

The study will include three oral dose regimens of R7128 (500 mg, 1000 mg and 1500 mg) in patients chronically infected with HCV genotype 1 and one oral dose regimen of R7128 (1500 mg) in patients chronically infected with HCV genotypes 2 or 3. All four dose regimens are being administered twice-daily with Pegasys plus Copegus for 4 weeks.

Food and Drug Administration (FDA) for PSI-7977 for the treatment of chronic hepatitis C virus (HCV) infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1.

First of all I am not sure what is normal for you ? Do you have HCV or were you being tested to see if you have HCV ?

SVR for Pegasys plus Copegus combination therapy is 44-51% for genotype 1, and 70-82% for genotypes 2 through 6. Pegasys is a ready-made solution that is dosed at 180µg regardless of a person's weight. The FDA has also approved Pegasys for treatment of chronic hepatitis B and Pegasys plus Copegus for the treatment of people with HIV and hepatitis C coinfection.

Three months ago, I completed 36 weeks of treatment (Peg + Copeg) for HCV, Genotype I. I was UND at 12, 24, and 36 weeks. I had many of the side-effects during treatment and after treatment as well. Now at three months post-treatment, I have been diagnosed with hypothyroidism (under-active thyroid) and this appears to explain my symptoms. It seems hypothyroidism has symptoms similar to depression. My doctor has prescribed replacement hormone therapy with a drug called Euthyrox.

//www.drugs.com/clinical_trials/victrelis-boceprevir-merck-s-investigational-medicine-added-peginterferon-alfa-2a-ribavirin-11404.

This is good news for eligible patients as previously, all patients with genotype 2 or 3 hepatitis C (HCV) received 24 weeks of Pegasys/Copegus therapy, regardless of their baseline virus levels and response while on treatment. The approval marks an important milestone in a new treatment concept in hepatitis C, which is called "response-guided therapy" and seeks to customise regimens for patients based on how well they respond to treatment.

I was diagnosed with hypothyroidism in 2000, after the birth of my son. I was also diagnosed with Hcv geno type 1 about 6 years ago. I started triple therapy tx with Sovaldi almost five weeks ago and have been researching hep c information relentlessly. ( this is also my 1st tx) Can someone tell me if my hypothyroidism may have a chance of going hyper? I currently am taking levothyroxine to treat the thyroid condition & have done well. Any information on this would be greatly appreciated.

1. Diagnosed with HCV May 2002 2. Enzymes spiked in July 2002 to 1052 (SGOT) & 1588 (SGPT) -- we never did figure out why they spiked 3. Liver biopsy performed in September 2002 -- Results were inflammation Grade 3 & fibrosis Stage 3 4. Treated with dual therapy (peg & riba) in 2002-2003 -- Went UNDetectable, but eventually became a BREAKTHROUGH 5. Received liver maintenance therapy with Pegasys (full dosages) for about a year in 2005 6.

Dosing schedules for pegasys and pegintron are different, pegintron is weight based and pegasys is not, it appears that you are taking pegasys 2.1 PegIntron Combination Therapy Adults The recommended dose of PegIntron is 1.5 mcg/kg/week. The volume of PegIntron to be injected depends on the strength of PegIntron and patient’s body weight (see Table 1). To see table 1 follow the link and go to prescribing info http://www.pegintron.com/peg/pegintron/consumer/index.

I was diagnose having hepa C virus as early as December 21, 2000while undergoing routine company medical check-up. Hepatitist C Antigen Test was taken on July 30, 2001 and with result of "Positive for the presence of HC-RNA.” Conbination Therapy of Interperon and rebairin was made for 4 months and Hepatitist PCR Assay Test was performed on April 25, 2002 where the result was "HCV-RNA not detected".

Has anybody out there been treated with COPEGUS and PEGASYS? I saw a gastroentoligist today and he has ordered all sorts of blood work, but says if I start treatment this is what he would give me. I asked about the new VERTEX drug coming out next year and he said it probably wouldent be out that soon.

J Viral Hepat. 2007 Oct;14(10):721-9 Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, MO 63110, USA. ***@**** Patients infected with hepatitis C virus (HCV) genotype 1 and with serum HCV RNA concentrations over 800 000 IU/mL have relatively low rates of virologic response to pegylated interferons.

My daughter had bone marrow transplant in November 2009. she was incidentally found to be HCV positive. Had HCV RNA qualitative which was negative. Presence of antibodies which means that she got infected but recovered (as told by my doctor). BMT done. now doctors have opinion that the HCV got reactivated due to use of immunosuppresant. Met two gastroenterologist, both have divergent views regarding interferon treatment. Neither of them had previously treated post BMT case. Guys!

Is there any research on the benefits of extending Pegasys and RibaPak treatment for hep c type 2 from 24 weeks to 36 weeks? My doctor is recommending 36 weeks and my insurance will only pay for 24.

My Test Results shows 9,822,742 IU/ml Result with HCV RNA Viral Load detection limit: 25 - 391,000,000 IU/mL. what this mean please?

I think the efficacy is pretty much equal with Pegasys perhaps having a slight edge. It was the tolerability of Pegasys that enabled me to extend my treatment duration and achieve SVR.

The exact number of patients co-infected with HCV and HBV is unknown. In patients with chronic hepatitis B, estimates of the rates of HCV co-infection vary from 9% to 30%. The primary concern with HBV/HCV co-infection is that it can lead to more severe liver disease and an increased risk for progression to liver cancer (HCC). Treatment of HBV/HCV co-infected patients can represent a challenge.

Common Questions and Answers about Pegasys hcv

pegasys